Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“The primary outcome of ACCORD (nonfatal MI, nonfatal stroke, or cardiovascular death) was nonsignificantly lower in the intensive glycemic control group due to a reduction in nonfatal MI, both when the glycemic control comparison was halted and all participants transitioned to the standard glycemic control interventio…”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
“aged patients—threefold that associated with conventional therapy [129].”
BackgroundManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
“group, due to a reduction in nonfatal MI, both when the glycemic control intervention was halted (81) and at completion of the planned follow-up (85).”
Background(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Insulin Resistance, Hyperglycemia, and Atherosclerosis
Bornfeldt, K. E., & Tabas, I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.015 · Cited by 995
Fenton, J. J. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1662 · Cited by 911
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
“Severe hypoglycemia occurs more frequently with intensive glycemic control (72,75,77,79).”
BackgroundThe amazing potential of fungi: 50 ways we can exploit fungi industrially
Hyde, K. D., Xu, J., Rapior, S., Jeewon, R., Lumyong, S., Niego, A. G. T., Abeywickrama, P. D., Aluthmuhandiram, J. V. S., Brahamanage, R. S., Brooks, S., et al. (2019) · Fungal Diversity · doi:10.1007/s13225-019-00430-9 · Cited by 811
“There are many negative consequences for patients if diabetes remains untreated, such as blindness, kidney failure, depression, cardiovascular diseases, cancer and even death (Gerstein et al. 2011; Hansen et al. 2012; Huang et al. 2018).”
BackgroundCKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Daskalopoulou, S. S., Rabi, D. M., Zarnke, K. B., Dasgupta, K., Nerenberg, K., Cloutier, L., Gelfer, M., Lamarre-Cliche, M., Milot, A., Bolli, P., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.016 · Cited by 684
“The appropriate target for a glycaemic control has been explored recently in the ADVANCE [664], ACCORD [665], and Veterans’ Affairs Diabetes Trial (VADT) [666] studies, which randomized one study arm to very low HbA1c targets (<6.”
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia
Umpierrez, G., & Korytkowski, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.15 · Cited by 563
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., Jessup, M., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 522
Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications
Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06320.x · Cited by 521
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Diabetes, hyperglycaemia, and acute ischaemic stroke
Luitse, M. J., Biessels, G. J., Rutten, G. E., & Kappelle, L. J. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70005-4 · Cited by 463
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“Severe hypoglycemia occurs more frequently with intensive glycemic control (75,78,80,84).”
BackgroundMancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2013.812549 · Cited by 426
Qaseem, A., Wilt, T. J., Kansagara, D., Horwitch, C., Barry, M. J., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2018) · Annals of Internal Medicine · doi:10.7326/m17-0939 · Cited by 412
Calderón‐Larrañaga, A., Vetrano, D. L., Ferrucci, L., Mercer, S. W., Marengoni, A., Onder, G., Eriksdotter, M., & Fratiglioni, L. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12843 · Cited by 408
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Hallberg, S. J., McKenzie, A. L., Williams, P. T., Bhanpuri, N. H., Peters, A. L., Campbell, W. W., Hazbun, T. L., Volk, B. M., McCarter, J. P., Phinney, S. D., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0373-9 · Cited by 406
Chow, E., Bernjak, A., Williams, S., Fawdry, R. A., Hibbert, S., Freeman, J., Sheridan, P. J., & Heller, S. R. (2014) · Diabetes · doi:10.2337/db13-0468 · Cited by 403
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Jenkins, D. J. A., Kendall, C. W. C., Augustin, L. S. A., Mitchell, S., Sahye-Pudaruth, S., Blanco Mejia, S., Chiavaroli, L., Mirrahimi, A., Ireland, C., Bashyam, B., et al. (2012) · Archives of Internal Medicine · doi:10.1001/2013.jamainternmed.70 · Cited by 392
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 363
Murea, M., Ma, L., & Freedman, B. I. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.6 · Cited by 366
“The negative impact of tight glycemic control was maintained in the long term follow-up, further suggesting the presence of a glycemic memory phenomenon in diabetic vascular complications [142].”
BackgroundEdgar, L., Akbar, N., Braithwaite, A. T., Krausgruber, T., Gallart-Ayala, H., Bailey, J., Corbin, A. L., Khoyratty, T. E., Chai, J. T., Alkhalil, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046464 · Cited by 340
Japanese Clinical Practice Guideline for Diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13306 · Cited by 341
Kullo, I. J., & Rooke, T. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1507631 · Cited by 333
Chew, E. Y., Davis, M. D., Danis, R. P., Lovato, J. F., Perdue, L. H., Greven, C., Genuth, S., Goff, D. C., Leiter, L. A., Ismail-Beigi, F., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.019 · Cited by 324
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska, K. J., Krumholz, H., Soones, T., & Lee, S. J. (2016) · JAMA · doi:10.1001/jama.2016.0299 · Cited by 309
Sinclair, A. J., Paolisso, G., Castro, M., Bourdel-Marchasson, I., Gadsby, R., & Rodriguez Mañas, L. (2011) · Diabetes & Metabolism · doi:10.1016/s1262-3636(11)70962-4 · Cited by 298
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“Severe hypoglycemia occurs more frequently with intensive glycemic control in RCTs where insulin and/or sulfonylureas (SUs) are utilized (173,176,180,182,183).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 286
Wilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & for the Dapagliflozin 006 Study Group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 291
“0% remains appropriate in younger patients [23,24] based on analyses of the UKPDS trial [25–27], for older patients—especially those with a prolonged duration of diabetes, at risk of severe hypoglycaemia, or with comorbidities—a higher target may be warranted based upon more recent analyses from the ACCORD and VADT tr…”
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 291
The Past 200 Years in Diabetes
Polonsky, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1110560 · Cited by 264
Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2334 · Cited by 259
Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers
Lyons, T. J., & Basu, A. (2012) · Translational Research · doi:10.1016/j.trsl.2012.01.009 · Cited by 250
“Studies over the past two decades have yielded sample sets (mostly blood products and urine) from large cohorts of people with both type 1 and type 2 diabetes that have been collected longitudinally over time, with detailed documentation of clinical outcomes [14-17].”
Aguayo‐Mazzucato, C., Diaque, P., Hernandez, S., Rosas, S., Kostic, A., & Caballero, A. E. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3097 · Cited by 246
Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship?
Vallianou, N. G., Mitesh, S., Gkogkou, A., & Geladari, E. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180711124825 · Cited by 237
Pasinetti, G. M., Wang, J., Ho, L., Zhao, W., & Dubner, L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.006 · Cited by 239
Obesity, Diabetes, and Cardiovascular Diseases: A Compendium
Scherer, P. E., & Hill, J. A. (2016) · Circulation Research · doi:10.1161/circresaha.116.308999 · Cited by 237
“This is especially relevant as rigid control of hyperglycemia, however central to treatment, has not fulfilled hopes of meaningful morbidity and mortality benefit.(3) Recent and ongoing research into mechanisms of metabolic control, insulin resistance, and diabetes-associated derangements portend novel therapies desig…”
BackgroundSGLT2i: beyond the glucose-lowering effect
Ni, L., Yuan, C., Chen, G., Zhang, C., & Wu, X. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01071-y · Cited by 230
The Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Hempe, J. M., Liu, S., Myers, L., McCarter, R. J., Buse, J. B., & Fonseca, V. (2015) · Diabetes Care · doi:10.2337/dc14-1844 · Cited by 233
Dementia, stroke, and vascular risk factors; a review
Sahathevan, R., Brodtmann, A., & Donnan, G. A. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00731.x · Cited by 230
Cardiovascular disease in diabetes, beyond glucose
Eckel, R. H., Bornfeldt, K. E., & Goldberg, I. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.001 · Cited by 212
Heart Failure in Patients with Diabetes Mellitus
Rosano, G. M., Clinical Academic Group Cardiovascular, S. G. H. N. T. M. S., Vitale, C., Department of Medical Sciences, I. S. R., Seferovic, P., & Department of Cardiology, U. O. B. (2017) · Cardiac Failure Review · doi:10.15420/cfr.2016:20:2 · Cited by 206
The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1309610 · Cited by 204
Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management
Zanon Zotin, M. C., Sveikata, L., Viswanathan, A., & Yilmaz, P. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000913 · Cited by 194
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub3 · Cited by 203
RetractedDifferential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects
Bouter, K. E., Bakker, G. J., Levin, E., Hartstra, A. V., Kootte, R. S., Udayappan, S. D., Katiraei, S., Bahler, L., Gilijamse, P. W., Tremaroli, V., et al. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0025-4 · Cited by 194
Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction
Maruhashi, T., & Higashi, Y. (2021) · Antioxidants · doi:10.3390/antiox10081306 · Cited by 185
Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes
The ACCORD Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2283 · Cited by 193
Self-citationStroke Prevention - Medical and Lifestyle Measures
Sarikaya, H., Ferro, J., & Arnold, M. (2015) · European Neurology · doi:10.1159/000367652 · Cited by 189
Workgroup, A. C. W. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12226 · Cited by 188
Williamson, J. D., Launer, L. J., Bryan, R. N., Coker, L. H., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M. D., Horowitz, K. R., Ding, J., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13656 · Cited by 187
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Leiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Gause‐Nilsson, I., Sugg, J., & Parikh, S. J. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12881 · Cited by 182
“In older adults with long-term diabetes mellitus and CVD, physicians often refrain from stringent glycemic regulation to avoid hypoglycemia, which has been associated with mortality in diabetes mellitus.(7,26,27) This treatment practice was reflected in the observed minimal uptitration of insulin after the protocol-ma…”
BackgroundJapanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12810 · Cited by 181
Rodríguez-Gutiérrez, R., & Montori, V. M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002901 · Cited by 176
Fu, L., Zhou, Y., Sun, J., Zhu, Z., Xing, Z., Zhou, S., Wang, Y., & Tai, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01393-5 · Cited by 164
Sulfonylureas: A New Look at Old Therapy
Thulé, P. M., & Umpierrez, G. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0473-5 · Cited by 165
Usman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., Sreenivasan, J., & Golzar, Y. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318755531 · Cited by 160
Sussman, J. B., Kerr, E. A., Saini, S. D., Holleman, R. G., Klamerus, M. L., Min, L. C., Vijan, S., & Hofer, T. P. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.5110 · Cited by 160
Severe Hypoglycemia Predicts Mortality in Diabetes
Cryer, P. E. (2012) · Diabetes Care · doi:10.2337/dc12-0749 · Cited by 158
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Martinez, M., Santamarina, J., Pavesi, A., Musso, C., & Umpierrez, G. E. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002032 · Cited by 155
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
White, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.004 · Cited by 152
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
Avogaro, A., & Fadini, G. P. (2014) · Diabetes Care · doi:10.2337/dc14-0865 · Cited by 164
The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications
Horváth, B., Mukhopadhyay, P., Haskó, G., & Pacher, P. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.11.003 · Cited by 176
“For example, although intensive glucose-lowering therapy reduces glycated hemoglobin levels, it increases 5-year mortality compared with standard therapy (ACCORD trial).(48) The understanding of the pathogeneses of microvascular and macrovascular complications in diabetes is paramount for the development of new therap…”
BackgroundThe relationship between bipolar disorder and type 2 diabetes: More than just co-morbid disorders
Calkin, C. V., Gardner, D. M., Ransom, T., & Alda, M. (2013) · Annals of Medicine · doi:10.3109/07853890.2012.687835 · Cited by 151
Gaps and barriers in the control of blood glucose in people with type 2 diabetes
Blonde, L., Aschner, P., Bailey, C., Ji, L., Leiter, L. A., Matthaei, S., & Management, O. B. O. T. G. P. F. E. D. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116679775 · Cited by 146
Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis?
Solomon, D. H., Bitton, A., Katz, J. N., Radner, H., Brown, E. M., & Fraenkel, L. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38323 · Cited by 172
“It is noteworthy that, along with beneficial effects, tight control of hyperglycemia and hypertension has also been associated with serious risks, such as symptomatic hypoglycemia or hypotension, and even increased mortality in some subgroups with multiple comorbidities (21).”
Gerstein, H. C., Miller, M. E., Ismail-Beigi, F., Largay, J., McDonald, C., Lochnan, H. A., & Booth, G. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60611-5 · Cited by 151
Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
Cameron-Vendrig, A., Reheman, A., Siraj, M. A., Xu, X. R., Wang, Y., Lei, X., Afroze, T., Shikatani, E., El-Mounayri, O., Noyan, H., et al. (2016) · Diabetes · doi:10.2337/db15-1141 · Cited by 137
“cardiovascular events, including death [9].”
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.